JP2023539542A5 - - Google Patents
Info
- Publication number
- JP2023539542A5 JP2023539542A5 JP2022567359A JP2022567359A JP2023539542A5 JP 2023539542 A5 JP2023539542 A5 JP 2023539542A5 JP 2022567359 A JP2022567359 A JP 2022567359A JP 2022567359 A JP2022567359 A JP 2022567359A JP 2023539542 A5 JP2023539542 A5 JP 2023539542A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- composition according
- compound
- antagonist
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173595.8A EP3906922A1 (en) | 2020-05-07 | 2020-05-07 | New compositions and methods of treating covid-19 disease |
| EP20173595.8 | 2020-05-07 | ||
| PCT/EP2021/061919 WO2021224356A1 (en) | 2020-05-07 | 2021-05-05 | New compositions and methods of treating covid-19 disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539542A JP2023539542A (ja) | 2023-09-15 |
| JP2023539542A5 true JP2023539542A5 (https=) | 2024-05-09 |
Family
ID=70617050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567359A Pending JP2023539542A (ja) | 2020-05-07 | 2021-05-05 | Ｃｏｖｉｄ－１９疾患を処置する新規組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230157994A1 (https=) |
| EP (2) | EP3906922A1 (https=) |
| JP (1) | JP2023539542A (https=) |
| KR (1) | KR20240073720A (https=) |
| CN (1) | CN116133657A (https=) |
| AU (1) | AU2021269090A1 (https=) |
| BR (1) | BR112022022578A2 (https=) |
| CA (1) | CA3177779A1 (https=) |
| WO (1) | WO2021224356A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023517616A (ja) * | 2020-03-11 | 2023-04-26 | バイオラインアールエックス・リミテッド | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 |
| JP2023524522A (ja) * | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤 |
| WO2022197625A1 (en) * | 2021-03-15 | 2022-09-22 | Drugarray, Inc. | Combination therapy for treating covid-19 |
| WO2022197627A1 (en) * | 2021-03-15 | 2022-09-22 | Drugarray, Inc. | Combination therapy for treating covid-19 |
| WO2022197626A1 (en) * | 2021-03-15 | 2022-09-22 | Drugarray, Inc. | Combination therapy for treating covid-19 |
| EP4085910A1 (en) * | 2021-05-05 | 2022-11-09 | 4Living Biotech | Use of a compound such as plerixafor for treating a viral pulmonary disease |
| CN114099531A (zh) * | 2021-12-16 | 2022-03-01 | 中国人民解放军军事科学院军事医学研究院 | 一种药物在治疗新型冠状病毒肺炎中的应用 |
| WO2024092069A1 (en) * | 2022-10-26 | 2024-05-02 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors for treatment of neurological diseases |
| CN121039852A (zh) | 2023-06-07 | 2025-11-28 | 株式会社Lg新能源 | 锂金属电池及包含该锂金属电池的电池模组和电池包 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892563B2 (en) * | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| TW200811138A (en) * | 2006-06-12 | 2008-03-01 | Pfizer Prod Inc | Pharmaceuticals |
| US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
| CN110982945B (zh) * | 2020-03-04 | 2020-06-09 | 珠海丽珠试剂股份有限公司 | 一种检测2019新型冠状病毒的核酸组合物、试剂盒以及方法 |
-
2020
- 2020-05-07 EP EP20173595.8A patent/EP3906922A1/en not_active Withdrawn
-
2021
- 2021-05-05 AU AU2021269090A patent/AU2021269090A1/en not_active Abandoned
- 2021-05-05 EP EP21722910.3A patent/EP4146195A1/en not_active Withdrawn
- 2021-05-05 JP JP2022567359A patent/JP2023539542A/ja active Pending
- 2021-05-05 CA CA3177779A patent/CA3177779A1/en active Pending
- 2021-05-05 KR KR1020227041380A patent/KR20240073720A/ko active Pending
- 2021-05-05 CN CN202180033555.4A patent/CN116133657A/zh active Pending
- 2021-05-05 US US17/922,865 patent/US20230157994A1/en active Pending
- 2021-05-05 BR BR112022022578A patent/BR112022022578A2/pt not_active Application Discontinuation
- 2021-05-05 WO PCT/EP2021/061919 patent/WO2021224356A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539542A5 (https=) | ||
| US11786517B2 (en) | Methods of treatment using a JAK inhibitor compound | |
| JP2017203033A5 (https=) | ||
| US20230346812A1 (en) | Methods for treating sars cov-2 infections | |
| JP7826224B2 (ja) | Ｓａｒｓ－ｃｏｖ－２の治療のための方法及び組成物 | |
| EP3906922A1 (en) | New compositions and methods of treating covid-19 disease | |
| US20240043466A1 (en) | Solid forms of a nucleoside analogue and uses thereof | |
| WO2021209740A1 (en) | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection | |
| US20240051962A1 (en) | Solid forms of a nucleoside analogue and uses thereof | |
| US20230322813A1 (en) | Compounds and methods for treatment of viral infections | |
| CN118903419A (zh) | Pde抑制剂或其盐在制备用于预防和/或治疗胃肠道疾病的药物中的用途 | |
| JP2018512428A5 (https=) | ||
| JP2022551477A5 (https=) | ||
| US20210292327A1 (en) | Deuterated toll-like receptor modulators | |
| US20230021647A1 (en) | Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l | |
| AU2024353008A1 (en) | Compounds and methods for treatment of viral infections | |
| JP2023527525A5 (https=) | ||
| JP2017535549A5 (https=) | ||
| US20250375398A1 (en) | Combination therapies for the treatment of viral infections | |
| EP4192452B1 (en) | Compositions comprising carboxyamidotriazole orotate for use in preventing or treating sars-cov-2 infection | |
| CN113164464A (zh) | 用于克服类固醇抗性的戊二酰亚胺衍生物 | |
| US20160235750A1 (en) | Small molecules targeting hiv-1 nef | |
| Allanore et al. | Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome | |
| GB2594480A (en) | New treatment | |
| Nelson et al. | Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV/HCV co-infection |